Latest Breaking News On - Theresa matkovits - Page 1 : comparemela.com

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc - Appili Therapeutics (OTC:APLIF), Aditxt (NASDAQ:ADTX)

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED

United statesAmro albannaDon cillaJenna mcneilJurgen froehlichTheresa matkovitsNelson mullins riley scarboroughAppili special committeeAditxt incLong zone holdingsDentons canadaAdivir incRichter hamptonRecommendation of appili special committeeAird berlisBloom burton securities inc

Matinas BioPharma Holdings, Inc (AMEX:MTNB) Q4 2023 Earnings Call Transcript

Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

New jerseyUnited statesJulian harrisonTerri matkovitsTerry fergusonAsia pacificKeith kucinskiJerome jabbourMatinas biopharmaJames fergusonJerry jabbourRobert leboyerTheresa matkovitsJody cainExchange commissionCompassionate expanded use access program

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

20.02.2024 - ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients . Seite 1

United statesJeromed jabbourTheresa matkovitsCompassionate expanded use access programDrug administrationExpanded use access programChief development officerChief executive officerMatinas biopharma holdings chartAtinas biopharma holdings kursAtinas biopharma holdings aktie

Matinas Biopharma Successfully Reaches Agreement With FDA For A Single Phase 3 Registration Trial To Support An NDA For MAT2203 For The Treatment Of I

Matinas Biopharma Successfully Reaches Agreement With FDA For A Single Phase 3 Registration Trial To Support An NDA For MAT2203 For The Treatment Of I
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesTheresa matkovitsMatinas biopharmaJeromed jabbourJody cainAsia pacificInfectious diseases society of americaWorld health organizationCompassionate expanded use access programDrug administrationData review committeeTreatment optionsExpanded use access programChief development officerChief executive officerData safety monitoring board

Matinas BioPharma (MTNB) Announces Patient with Candida krusei Infection in Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Matinas BioPharma (MTNB) Announces Patient with Candida krusei Infection in Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTheresa matkovitsMarisah miceliDivision of infectious diseasesUniversity of michiganMatina expanded access compassionate use programMatinas biopharmaMatina expandedCompassionate use programFungal infectionsTransplant diseasesInfectious diseasesInternal medicineChief development officerExpanded access